District Of Columbia is currently home to 860 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Washington, Washington, D.C., Washington DC and Washington, Dc. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
NCT04079179
Recruiting
This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorders that has returned or does not respond to treatment. Cobimetinib blocks activation of a protein called Mitogen-activated protein kinase (MEK) that is part of incorrect growth signals in histiocytosis cells. Four different groups of patients will be enrolled.
Gender:
ALL
Ages:
All
Trial Updated:
06/17/2025
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma, Erdheim-Chester Disease, Rosai Dorfman Disease, Neuro-Degenerative Disease, Histiocytic Sarcoma, Histiocytic Disorders, Malignant
Register for Updates
IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT07032662
Recruiting
This is a Phase 2b study to evaluate the efficacy and safety of IMVT-1402 in adults with CIDP.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Site Number - 1630, Washington, District of Columbia
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Register for Updates
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
NCT06581406
Recruiting
The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor therapy.
Gender:
ALL
Ages:
All
Trial Updated:
06/16/2025
Locations: Georgetown University Medical Center, Washington, District of Columbia
Conditions: Metastatic Uveal Melanoma
Register for Updates
A Study of Auxora in Patients With AKI and Injurious Lung "Crosstalk"
NCT06374797
Recruiting
Approximately 150 patients with acute kidney injury (AKI) associated with acute hypoxemic respiratory failure (AHRF) will be randomized at up to 40 sites. Patients will be randomly assigned to either Auxora or matching placebo. Study drug infusions will occur every 24 hours for five consecutive days for a total of five infusions.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Medstar Washington Hospital Center, Washington DC, District of Columbia
Conditions: Acute Kidney Injury
Register for Updates
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3)
NCT06264180
Recruiting
This is a randomized, controlled, multicenter, open-label Phase 3 clinical study comparing VO in combination with nivolumab versus Physician's Choice treatment for patients with unresectable Stage IIIb-IV cutaneous melanoma whose disease progressed on an anti PD-1 and an anti-CTLA-4 containing regimen (administered either as a combination regimen or in sequence) or who are not candidates for treatment with an anti-CTLA-4 therapy.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/16/2025
Locations: MedStar Washington Hospital Center, Washington, District of Columbia
Conditions: Advanced Melanoma
Register for Updates
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
NCT05985161
Recruiting
The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, or another solid tumor that makes a higher than normal amount of XPO1 or has genetic changes that increase the activity of XP01.
Gender:
ALL
Ages:
12 months and above
Trial Updated:
06/16/2025
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Wilms Tumor, Rhabdoid Tumor, Malignant Peripheral Nerve Sheath Tumors, MPNST, Nephroblastoma, XPO1 Gene Mutation, Solid Tumor
Register for Updates
Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
NCT05416307
Recruiting
Hemophagocytic lymphohistiocytosis is a rare, aggressive and life-threatening syndrome of excessive immune activation. Secondary hemophagocytic lymphohistiocytosis (sHLH) is the most common form of this disease and is typically associated with several other clinical conditions (eg, malignancy associated HLH (mHLH), infection, or autoimmune disease). ELA026 is a fully human immunoglobulin G1 (IgG1) signal regulatory protein (SIRP)-directed monoclonal antibody designed to deplete the myeloid and T... Read More
Gender:
ALL
Ages:
6 years and above
Trial Updated:
06/16/2025
Locations: MedStar Georgetown, Washington, District of Columbia
Conditions: Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Register for Updates
Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature
NCT04674969
Recruiting
The ELEGANCE Registry's objective is to collect Real-World Data (RWD), including populations previously not represented in Peripheral Vascular Disease (PVD) trials, health economics data, and to support the safe use of commercially available Boston Scientific Corporation (BSC) drug-eluting devices for the treatment of lesions located in the peripheral vasculature.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Washington Hospital Center, Washington, District of Columbia
Conditions: Peripheral Vascular Diseases
Register for Updates
Sleep for Stroke Management and Recovery Trial
NCT03812653
Recruiting
The purpose of this study is to determine whether treatment of obstructive sleep apnea (OSA) with positive airway pressure starting shortly after acute ischemic stroke (1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after the event, and (2) improves stroke outcomes at 3 months in patients who experienced an ischemic stroke.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: George Washington University Hospital, Washington, District of Columbia
Conditions: Ischemic Stroke, Sleep Apnea, Sleep Apnea, Obstructive, Stroke, CPAP, Telemedicine, Home Sleep Apnea Test, Randomized Clinical Trial, Multicenter Trial
Register for Updates
National Collaborative to Improve Care of Children With Complex Congenital Heart Disease
NCT02852031
Recruiting
The purpose of this initiative is to improve care and outcomes for infants with HLHS by expanding the NPC-QIC national registry to gather clinical care process, outcome, and developmental data on infants with HLHS between diagnosis and 12 months of age, by improving the use of standards into everyday practice across pediatric cardiology centers, and by engaging parents as partners in the process.
Gender:
ALL
Ages:
15 months and below
Trial Updated:
06/16/2025
Locations: Children's National Medical Center, Washington DC, District of Columbia
Conditions: Hypoplastic Left Heart Syndrome (HLHS)
Register for Updates
Zenith® Fenestrated+ Clinical Study
NCT04875429
Recruiting
The Zenith® Fenestrated+ Endovascular Graft Clinical Study will assess the safety and effectiveness of the Zenith® Fenestrated+ Endovascular Graft (ZFEN+) in combination with the BeGraft Balloon-Expandable FEVAR Bridging Stent Graft System (BeGraft) and Unibody2 for the treatment of patients with aortic aneurysms involving one or more of the major visceral arteries.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/15/2025
Locations: Medstar Washington Hospital Center, Washington, District of Columbia
Conditions: Aortic Aneurysm, Abdominal, Juxtarenal Aortic Aneurysm, Extent IV Thoracoabdominal, Pararenal Aneurysm
Register for Updates
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
NCT06521554
Recruiting
Phase 1a/1b dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-330, determine the recommended Phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced or metastatic HER2-altered NSCLC. Phase 1a dose escalation is designed to assess the safety and tolerability of NVL-330 and to select the candidate RP2D(s) and, if applicable, the MTD. Phase 1b expansion is designed to further evaluate the overall safety and tolerability of the c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Georgetown University Medical Center, Washington, District of Columbia
Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor
Register for Updates